Astragaloside IV demonstrates cardioprotective effects against post-MI remodeling and fibrosis in preclinical models by inhibiting macrophage pyroptosis.
, AS-IV was selected to stimulate bone marrow-derived macrophages (BMDMs). Our findings indicated that AS-IV protective effect of the heart might be related to the reduction of macrophage pyroptosis. These results demonstrate that AS-IV alleviated MI-induced myocardial fibrosis and cardiac remodeling by suppressing ROS/Caspase-1/GSDMD signaling pathway, AS-IV should be further studied in the future.
Zhang et al. (Thu,) studied this question.